MRKR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

682.00K

-69.71%

-0.197

-53.17%

600.00K

+71.87%

-0.220

-45%

600.00K

-30.33%

-0.270

-6.9%

Estimates Revision

The market is revising No Change the revenue expectations for Marker Therapeutics, Inc. (MRKR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 39.73%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+39.73%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast MRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRKR is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.390

Low

8.00

Averages

8.00

High

8.00

Current: 1.390

Low

8.00

Averages

8.00

High

8.00

H.C. Wainwright

Patrick Trucchio

Buy

initiated

$10

2025-12-08

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$10

2025-12-08

initiated

Buy

Reason

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Marker Therapeutics with a Buy rating and $10 price target. The company's pipeline of non-genetically engineered T cell-based immunotherapies has the potential to overcome safety, efficacy, and scalability limitations of single-antigen targeted immunotherapy modalities including chimeric antigen receptor T cells, the analyst tells investors in a research note. The firm says Marker is advancing both autologous and allogeneic MAR-T cell therapies through clinical development as part of its wholly-owned pipeline. H.C. Wainwright believes MAR-T cell therapies position Marker as an emerging leader across the "competitive" space of cancer immunotherapy.

WBB Securities

Steve Brozak

Strong Buy

Reiterates

$13

2025-04-01

Reason

WBB Securities

Steve Brozak

Price Target

$13

2025-04-01

Reiterates

Strong Buy

Reason

Canaccord Genuity

John Newman

Strong Buy

Initiates

2025-03-05

Reason

Canaccord Genuity

John Newman

Price Target

2025-03-05

Initiates

Strong Buy

Reason

Canaccord initiated coverage of Marker Therapeutics with a Buy rating and $8 price target.

Valuation Metrics

The current forward P/E ratio for Marker Therapeutics Inc (MRKR.O) is -1.46, compared to its 5-year average forward P/E of -1.90. For a more detailed relative valuation and DCF analysis to assess Marker Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.90

Current PE

-1.46

Overvalued PE

-0.49

Undervalued PE

-3.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.02

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.12

Undervalued EV/EBITDA

-0.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.81

Current PS

0.00

Overvalued PS

17.24

Undervalued PS

-3.62

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MRKR News & Events

Events Timeline

No data

News

3.5

12-11Globenewswire

Merakris Presents MTX-001 Biologic Drug at Innovations in Wound Healing Symposium

9.5

11-14Newsfilter

Marker Therapeutics Announces Financial Results for Q3 2025 and Shares Business Developments

9.0

11-03Newsfilter

Marker Therapeutics to Present MT-601 Data for Relapsed Non-Hodgkin and Hodgkin Lymphoma at 67th ASH Annual Meeting

People Also Watch

Frequently Asked Questions

What is Marker Therapeutics Inc (MRKR) stock price today?

The current price of MRKR is 1.39 USD — it has decreased -5.44 % in the last trading day.

What is Marker Therapeutics Inc (MRKR)'s business?

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

What is the price predicton of MRKR Stock?

What is Marker Therapeutics Inc (MRKR)'s revenue for the last quarter?

Marker Therapeutics Inc revenue for the last quarter amounts to 1.23M USD, decreased -35.99 % YoY.

What is Marker Therapeutics Inc (MRKR)'s earnings per share (EPS) for the last quarter?

Marker Therapeutics Inc. EPS for the last quarter amounts to -0.12 USD, decreased -53.85 % YoY.

What changes have occurred in the market's expectations for Marker Therapeutics Inc (MRKR)'s fundamentals?

How many employees does Marker Therapeutics Inc (MRKR). have?

Marker Therapeutics Inc (MRKR) has 5 emplpoyees as of December 16 2025.

What is Marker Therapeutics Inc (MRKR) market cap?

Today MRKR has the market capitalization of 23.18M USD.